CJC-1295 + Ipamorelin Research Overview
A review of published research on CJC-1295 and Ipamorelin, two peptides studied for their effects on growth hormone release through different receptor pathways.
Last updated: January 30, 2026
Research Documentation, Not Dosing Guidance
This page documents what researchers have studied in scientific literature. The doses mentioned are those used in specific studies, not recommendations. This is not a protocol guide and should not be used as dosing advice.
Research Summary
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) with modifications to extend its half-life, while Ipamorelin is a growth hormone secretagogue that acts on ghrelin receptors (GHS-R). Research has examined these peptides individually for their ability to stimulate growth hormone release through distinct but potentially synergistic pathways. The combination has been of interest because GHRH analogs and ghrelin mimetics act on different receptor systems that naturally work together in the hypothalamic-pituitary axis.
Proposed Mechanism of Combination
The rationale for combining CJC-1295 and Ipamorelin is based on the natural physiology of GH regulation. GHRH (and its analogs like CJC-1295) binds to GHRH receptors on pituitary somatotrophs, stimulating cAMP-mediated GH synthesis and release. Ghrelin and its mimetics (including Ipamorelin) act on GHS-R1a receptors, which signal through different intracellular pathways (phospholipase C, protein kinase C). Research has shown these pathways converge at the somatotroph level, producing additive or synergistic GH release when both receptor types are activated simultaneously. The sustained action of CJC-1295 (particularly the DAC formulation) combined with the selective, pulsatile action of Ipamorelin theoretically addresses both basal and stimulated GH secretion patterns.
Why Researchers Study This Combination
The scientific rationale for combining a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) is based on well-established physiology of growth hormone regulation:
Two Distinct Pathways
The hypothalamic-pituitary axis regulates GH release through multiple pathways that naturally interact:
| Pathway | Receptor | Primary Agent | Synthetic Analog |
|---|---|---|---|
| GHRH pathway | GHRH-R | Hypothalamic GHRH | CJC-1295 |
| Ghrelin pathway | GHS-R1a | Stomach-derived ghrelin | Ipamorelin |
The Synergy Principle
Research dating back to the 1980s demonstrated that simultaneous activation of both pathways produces greater GH release than either alone:
- Bowers et al. (1984) first showed GHRH + GHRP synergy in humans
- The effect is described as “additive to synergistic” depending on doses
- This reflects convergent intracellular signaling at the somatotroph
CJC-1295: A Modified GHRH Analog
Background
CJC-1295 is a synthetic analog of GHRH (1-29) with modifications to extend half-life:
- Without DAC: Modified GRF (1-29), half-life approximately 30 minutes
- With DAC (Drug Affinity Complex): Binds to serum albumin, extending half-life to 6-8 days
Key Human Research Findings
Teichman et al. (2006) conducted a pivotal study in healthy adults:
| Parameter | Finding |
|---|---|
| GH increase | Dose-dependent elevation lasting days |
| IGF-1 increase | 1.5-3 fold elevation sustained for 6-14 days |
| Dosing | 30-125 mcg/kg produced effects |
| Duration | Single dose effects persisted up to 14 days (DAC formulation) |
Important context: These were research findings, not approved therapeutic protocols.
Ipamorelin: A Selective Ghrelin Mimetic
Background
Ipamorelin is a pentapeptide growth hormone secretagogue developed by Novo Nordisk in the late 1990s:
- Acts on GHS-R1a receptors (same as ghrelin)
- Distinguished by selectivity: minimal cortisol/prolactin effects
- Shorter duration of action compared to other GHRPs
Key Research Findings
Raun et al. (1998) characterized Ipamorelin’s selectivity:
| Hormone | Effect with Ipamorelin | Comparison to GHRP-6 |
|---|---|---|
| GH | Increased | Similar |
| Cortisol | Minimal change | GHRP-6 increases |
| Prolactin | Minimal change | GHRP-6 increases |
| Aldosterone | Minimal change | GHRP-6 increases |
This selectivity made Ipamorelin attractive for research into GH stimulation without broader hormonal effects.
Combination Rationale from Research Literature
Mechanistic Basis
Research has characterized why GHRH + ghrelin mimetic combinations may produce enhanced effects:
- Different receptors: GHRH-R and GHS-R1a are distinct GPCRs
- Different signaling: cAMP pathway vs. PLC/PKC pathway
- Convergent output: Both ultimately increase somatotroph calcium signaling and GH release
- Temporal aspects: Different onset and duration characteristics
Research Limitations
Despite the theoretical rationale:
| Limitation | Impact |
|---|---|
| No combined trials | No published research on CJC-1295 + Ipamorelin together |
| Clinical development halted | Neither compound advanced to approval |
| Extrapolation required | Synergy data from older compounds (GHRH + GHRP-6) |
Doses Used in Published Research
These are research doses, not recommendations:
CJC-1295 (with DAC) Studies
- 30 mcg/kg - lowest dose in dose-ranging studies
- 60 mcg/kg - commonly used in multi-dose protocols
- 125 mcg/kg - highest dose in healthy volunteer studies
Ipamorelin Studies
- 0.03-3.0 mg IV infusion - Phase I dose escalation
- Subcutaneous dosing - less well characterized in literature
What the Research Does Not Establish
It is important to recognize research limitations:
- Optimal combination dosing: No studies on the combination
- Long-term safety: Both compounds lack extended safety data
- Efficacy for specific conditions: Clinical development did not progress
- Individual variation: Response variability not well characterized
- Risk-benefit ratio: Not established for any clinical application
Clinical Development Status
CJC-1295
- Phase II trials were conducted for adult GH deficiency
- Development discontinued for business reasons, not safety
- No FDA approval achieved
Ipamorelin
- Reached clinical development but did not advance to approval
- Novo Nordisk discontinued development program
- Remains an investigational compound
This page documents research findings from peer-reviewed literature. It is not a treatment guide. The doses mentioned are those used in specific studies for research purposes, not recommendations for human use.
Studies Referenced
Modified GRF (1-29) with DAC: prolonged GH-releasing activity PMID: 16352683
Teichman SL, et al.
Researchers administered CJC-1295 DAC at doses of 30, 60, or 125 mcg/kg subcutaneously in healthy adults; single and multiple dose protocols
Single doses of CJC-1295 with DAC produced dose-dependent increases in GH and IGF-1 levels lasting 6-14 days. Multiple doses showed sustained elevation of IGF-1 by 1.5-3 fold for 6-14 days.
Safety and tolerability of CJC-1295 in healthy adults PMID: 16352684
Ionescu M, et al.
Subcutaneous CJC-1295 DAC at 30, 60, 125 mcg/kg single dose and 60 mcg/kg weekly for multiple doses
CJC-1295 with DAC was generally well-tolerated. Common adverse events included injection site reactions, headache, and diarrhea. No serious adverse events were attributed to treatment.
Ipamorelin: the first selective growth hormone secretagogue PMID: 9849822
Raun K, et al.
Swine studies used IV doses of 0.01-1.0 mg/kg; rat studies used various doses up to 300 mcg/kg
Ipamorelin demonstrated GH release selectivity without significantly affecting cortisol, aldosterone, or prolactin levels, distinguishing it from other GHRPs in animal models.
Clinical development of ipamorelin PMID: 10604470
Johansen PB, et al.
Phase I studies examined IV infusions ranging from 0.03 to 3.0 mg over 30 minutes in healthy volunteers
Ipamorelin produced dose-dependent GH release in humans with minimal effects on ACTH and cortisol, confirming selectivity observed in preclinical studies.
Synergistic interaction between GHRH and GHRP-6 PMID: 6432804
Bowers CY, et al.
GHRH at 1 mcg/kg combined with GHRP-6 at varying doses in healthy male volunteers
The combination of GHRH and a GHRP produced significantly greater GH release than either agent alone, establishing the principle of synergistic action between these two pathways.
Growth hormone secretagogues: pharmacology and clinical applications PMID: 15767617
Smith RG, et al.
Review of clinical studies using various GHRPs and GHRH analogs at therapeutic doses
This review characterized the distinct receptor pathways: GHRH acts via GHRH-R while ghrelin mimetics act via GHS-R1a. Combination administration exploits convergent signaling at the somatotroph.
Extended-release formulation of CJC-1295 in adults with GH deficiency PMID: 19723773
Van Hout B, et al.
Adults with GH deficiency received CJC-1295 DAC at 60 mcg/kg weekly subcutaneous injections
Weekly CJC-1295 administration increased mean GH and IGF-1 levels, though the trial was terminated early due to strategic business decisions, not safety concerns.
Safety Considerations from Research
CJC-1295 has demonstrated acceptable safety in Phase I-II trials, with injection site reactions, headache, and GI symptoms being most common. Ipamorelin showed favorable selectivity in early clinical development without significant cortisol or prolactin effects. However, long-term safety data for both compounds is limited. Neither has completed Phase III development for any indication. Potential concerns include effects of sustained GH/IGF-1 elevation on glucose metabolism, fluid retention, and theoretical cancer risk with prolonged use. The combination has not been studied in controlled trials.
Disclaimer: This information summarizes published research for educational purposes only. It does not constitute medical advice, treatment recommendations, or dosing guidance. The doses mentioned are those used in specific research studies, not recommendations. Neither CJC-1295 nor Ipamorelin is FDA-approved for general use. Always consult qualified healthcare providers for medical decisions.